­
­
­
­

Inventi Impact: Pulmonology

Articles

  • Inventi:hpm/33277/20
    Impact of Reducing the Duration of Antibiotic Treatment on the Long-Term Prognosis of Community Acquired Pneumonia
    Research 2021 : January - March
    Ane Uranga MD, Amaia Artaraz MD, Amaia Bilbao MD, Jose María Quintana MD, Ignacio Arriaga MD, Maider Intxausti MD, Jose Luis Lobo MD, Julia Amaranta García MD, Jesus Camino MD, Pedro Pablo España MD

    Background: The optimal duration of antibiotic treatment for community-acquired pneumonia (CAP) is not well\nestablished. The aim of this study was to assess the impact of reducing the duration of antibiotic treatment on\nlong-term prognosis in patients hospitalized with CAP.\nMethods: This was a multicenter study assessing complications developed during 1 year of patients previously\nhospitalized with CAP who had been included in a randomized clinical trial concerning the duration of antibiotic\ntreatment. Mortality at 90 days, at 180 days and at 1 year was analyzed, as well as new admissions and\ncardiovascular complications. A subanalysis was carried out in one of the hospitals by measuring C-reactive protein\n(CRP), procalcitonin (PCT) and proadrenomedullin (proADM) at admission, at day 5 and at day 30......................

    How to Cite this Article
    Attribution/ CC Compliant Citation: Uranga, Ane, et al.\n\"Impact of reducing the duration of antibiotic treatment on\nthe long-term prognosis of community acquired pneumonia.\"\nBMC pulmonary medicine 20.1 (2020): 1-8.\nhttps://doi.org/10.1186/s12890-020-01293-6\nhttp://creativecommons.org/licenses/by/4.0/\nSome formatting elements, header, footer, logos, dates and\npagination were modified while adapting this article.
    Download Full Text